KDM5A Inhibitors Restore Antigen Presentation in Ovarian Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively enhance anti-tumor immune responses in cancers like epithelial ovarian cancer, as cancer cells evade immune surveillance by reducing expression of genes involved in antigen processing and presentation, particularly due to the action of KDM5A, which represses these genes, leading to decreased CD8+ T-cell infiltration and impaired immune response.
Innovation Solution
Administering a KDM5A inhibitor, such as CPI-455, to subjects with cancer to inhibit KDM5A activity, thereby restoring antigen presentation pathways and promoting CD8+ T-cell infiltration and anti-tumor immune responses, potentially in combination with cytotoxic agents, interferon gamma, or checkpoint inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cancer cells reduce expression of genes encoding MHC class I and antigen presentation machinery, then cancer cell viability is maintained, but immune surveillance is evaded and anti-tumor immune response is suppressed
Solution Approach 1:
The patent uses epigenetic modifiers (HDAC inhibitors, DNMT inhibitors, HMT inhibitors, KDM inhibitors) to change the epigenetic parameters of cancer cells, thereby restoring gene expression of MHC class I and antigen presentation machinery without altering the genetic sequence. This resolves the contradiction by modifying cellular parameters to enhance immune recognition while maintaining cancer cell viability.
Solution Approach 2:
The patent introduces epigenetic modifiers as intermediary substances that mediate between the cancer cells and the immune system. These modifiers restore antigen presentation capacity indirectly by altering epigenetic marks, rather than directly stimulating the immune system or genetically engineering the cancer cells.
2Reliability
If epigenetic regulators are targeted to restore antigen presentation, then CD8+ T cell infiltration is increased, but therapeutic complexity increases
Solution Approach 1:
The patent segments the complex problem of enhancing anti-tumor immunity into distinct epigenetic pathways (HDAC, DNMT, HMT, KDM) that can be targeted individually. Each epigenetic regulator class represents a separate therapeutic avenue, allowing researchers to select and optimize specific inhibitors rather than attempting to modulate all epigenetic mechanisms simultaneously.
Solution Approach 2:
The patent identifies multiple epigenetic regulator classes (HDAC, DNMT, HMT, KDM) that can all be targeted to achieve the same therapeutic goal of restoring antigen presentation. This multi-functionality provides therapeutic redundancy and flexibility, where different epigenetic inhibitors can be used interchangeably or in combination to achieve immune enhancement.
Data Source
AI summary
Methods of treating cancer, promoting antigen presentation, or increasing CD8+ T cell infiltration in tumors by inhibiting KDMA5 are provided.